Five Prime Therapeutics Return on Equity

Five Prime Therapeutics (FPRX) currently reports a ROE of -31.81%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Five Prime Therapeutics's ROE history and peer comparisons.

Five Prime Therapeutics's ROE of -31.81% is lower than the Healthcare sector average of 21.67%. That is roughly 246.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Five Prime Therapeutics's current -31.81% should be judged against Healthcare norms (sector average: 21.67%) and against FPRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -31.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Five Prime Therapeutics, and consider following FPRX for alerts when major investors trade the stock.

Five Prime Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -31.81% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FPRX with unrelated industries.